Healx raised $47 million in a Series C funding round led by R42 Group and Atomico to develop treatments for rare diseases including neurofibromatosis Type 1.
Healx raised $47 million in a Series C funding round led by R42 Group and Atomico to develop treatments for rare diseases including neurofibromatosis Type 1.
08/01/24, 11:04 AM
Location
cambridgeMoney raised
$47 million
Industry
therapeutics
artificial intelligence
biotechnology
health care
Round Type
series c
Investors
Vu Venture Partners, O2h, Ayana Capital, Btov, Global Brain, Jonathan Milner, Balderton, Atomico, R42 Group
Healx has announced the completion of a $47 million Series C financing to support its pipeline of medicines. The funding will advance the lead program HLX-1502 through a Phase 2 clinical trial for neurofibromatosis Type 1.
Company Info
Location
cambridge, england, united kingdom
Additional Info
Healx is an AI-enabled, clinical-stage biotech company specializing in rare diseases. Co-founded by its chairman David Brown and Tim Guilliams, its mission is to apply emerging technologies to accelerate the discovery of treatments for rare diseases. The company's pipeline includes innovative therapies targeting conditions such as neurofibromatosis Type 1, utilizing their proprietary Healnet discovery platform. Healx is committed to harnessing AI to identify and develop new therapeutic opportunities for patients with significant unmet medical needs.